Medtronic
MDT,
said the U.S. Food and Drug Administration has approved its PulseSelect Pulsed Field Ablation System for the treatment of two heart conditions.
The Dublin-based medical technology company on Wednesday said the company’s heart technology can now treat paroxysmal and persistent atrial fibrillation following the FDA’s approval.
Commercialization of the PulseSelect PFA system will start in early 2024.